Honeychurch J - Search Results

1

Investigating Radiotherapy Response in a Novel Syngeneic Model of Prostate Cancer.

Haughey CM, Mukherjee D, Steele RE, Popple A, Dura-Perez L, Pickard A, Patel M, Jain S, Mullan PB, Williams R, Oliveira P, Buckley NE, Honeychurch J, S McDade S, Illidge T, Mills IG, Eddie SL. Haughey CM, et al. Among authors: honeychurch j. Cancers (Basel). 2020 Sep 29;12(10):2804. doi: 10.3390/cancers12102804. Cancers (Basel). 2020. PMID: 33003551 Free PMC article.

2

Radioimmunotherapy in the pi-BCL1 B cell lymphoma model: efficacy depends on more than targeted irradiation alone.

Illidge T, Honeychurch J, Vandersteen A, Cragg M. Illidge T, et al. Among authors: honeychurch j. Cancer Biother Radiopharm. 2000 Dec;15(6):581-91. doi: 10.1089/cbr.2000.15.581. Cancer Biother Radiopharm. 2000. PMID: 11190490

3

Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma.

Honeychurch J, Glennie MJ, Johnson PW, Illidge TM. Honeychurch J, et al. Blood. 2003 Aug 15;102(4):1449-57. doi: 10.1182/blood-2002-12-3717. Epub 2003 Apr 24. Blood. 2003. PMID: 12714523 Free article.

4

Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells.

Honeychurch J, Glennie MJ, Illidge TM. Honeychurch J, et al. Cancer Res. 2005 Aug 15;65(16):7493-501. doi: 10.1158/0008-5472.CAN-04-3808. Cancer Res. 2005. PMID: 16103104

5

Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma.

Dovedi SJ, Melis MH, Wilkinson RW, Adlard AL, Stratford IJ, Honeychurch J, Illidge TM. Dovedi SJ, et al. Among authors: honeychurch j. Blood. 2013 Jan 10;121(2):251-9. doi: 10.1182/blood-2012-05-432393. Epub 2012 Oct 18. Blood. 2013. PMID: 23086756 Free article.

6

Immunogenic potential of irradiated lymphoma cells is enhanced by adjuvant immunotherapy and modulation of local macrophage populations.

Honeychurch J, Melis MH, Dovedi SJ, Mu L, Illidge TM. Honeychurch J, et al. Leuk Lymphoma. 2013 Sep;54(9):2008-15. doi: 10.3109/10428194.2013.769219. Epub 2013 Feb 18. Leuk Lymphoma. 2013. PMID: 23339450

7

Sustained tumour eradication after induced caspase-3 activation and synchronous tumour apoptosis requires an intact host immune response.

Melis MH, Simpson KL, Dovedi SJ, Welman A, MacFarlane M, Dive C, Honeychurch J, Illidge TM. Melis MH, et al. Among authors: honeychurch j. Cell Death Differ. 2013 May;20(5):765-73. doi: 10.1038/cdd.2013.8. Epub 2013 Feb 15. Cell Death Differ. 2013. PMID: 23412345 Free PMC article.

8

Synchronous apoptosis in established tumors leads to the induction of adaptive immunity.

Honeychurch J, Dive C, Illidge TM. Honeychurch J, et al. Oncoimmunology. 2013 Jun 1;2(6):e24501. doi: 10.4161/onci.24501. Epub 2013 Apr 16. Oncoimmunology. 2013. PMID: 23894711 Free PMC article.

9

A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models.

Adlard AL, Dovedi SJ, Telfer BA, Koga-Yamakawa E, Pollard C, Honeychurch J, Illidge TM, Murata M, Robinson DT, Jewsbury PJ, Wilkinson RW, Stratford IJ. Adlard AL, et al. Among authors: honeychurch j. Int J Cancer. 2014 Aug 15;135(4):820-9. doi: 10.1002/ijc.28711. Epub 2014 Jan 17. Int J Cancer. 2014. PMID: 24390981 Free PMC article.

10

Immuno-regulatory antibodies for the treatment of cancer.

Honeychurch J, Cheadle EJ, Dovedi SJ, Illidge TM. Honeychurch J, et al. Expert Opin Biol Ther. 2015 Jun;15(6):787-801. doi: 10.1517/14712598.2015.1036737. Epub 2015 Apr 16. Expert Opin Biol Ther. 2015. PMID: 25882106 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

51 results

Search Page